Developer docs
API playgroundTry for free, no card

Search company profiles

Click Therapeutics

Full company profile

uuid00003ga

Namestring
Click Therapeutics
Legal namestring
Click Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Click Therapeutics, Inc. is a New York City-based, venture-backed private digital therapeutics company founded in 2012 by David Benshoof Klein. The company develops, validates, and commercializes software as prescription medical treatments (Prescription Digital Therapeutics, or PDTs) for serious psychiatric, neurological, and cardiometabolic conditions. Its proprietary AI-enabled platform combines the Click Neurobehavioral Intervention (CNI) Platform with the Digital Neuroactivation and Modulation (DiNaMo) paradigm to deliver clinically-validated, smartphone-based cognitive and behavioral interventions that modulate neural circuits involved in depression, migraine, schizophrenia, diabetes, and other conditions. The platform supports both standalone PDTs and Click SE™ Software-Enhanced Drug™ combinations with pharmacotherapy under FDA's PDURS framework.

The company has secured three FDA-authorized products: Rejoyn (CT-152) for adjunctive MDD treatment (FDA-cleared April 2024), CT-132 for episodic migraine prevention (FDA De Novo authorization April 2025), and AspyreRx for type 2 diabetes (acquired via Better Therapeutics in May 2024). Its investigational pipeline spans schizophrenia (CT-155 in Phase III with positive CONVOKE results; CT-156 in Phase 2), opioid use disorder (CT-102 with Indivior), multiple sclerosis (CT-133), atopic dermatitis (CT-171), obesity optimized for GLP-1 combination (CT-181), oncology (CT-191), insomnia (CT-141/Clickadian), and acute coronary syndrome (CT-111/Clickheart). The FDA has granted Breakthrough Device Designations for CT-132, CT-155, and BT-004.

Click generates revenue through three primary streams: (1) licensing royalties and milestone payments from pharmaceutical co-development partners, with disclosed deal values exceeding $500M (Boehringer Ingelheim for CT-155/CT-156) and up to $302M (Otsuka for Rejoyn), plus tiered double-digit royalties on net sales; (2) direct prescription digital therapeutic sales via iOS/Android app stores reimbursed by Medicare and select commercial payers; and (3) B2B Click SE™ enterprise partnerships with pharma companies for software-enhanced drug development. Distribution is multi-channel, including prescription downloads, healthcare provider channels, pharma partner commercialization (Otsuka for Rejoyn globally; Click now leads CT-155 commercialization post-April 2026 restructuring), and OEM/embedded distribution via Ultrahuman's Ring Air smart ring (Migraine PowerPlug, launching early 2026 across the US, Canada, EU, India, and Australia). The company employs ~68 staff post-April 2026 layoffs and is led by founder/CEO David Benshoof Klein alongside a multidisciplinary executive team.

Short descriptiontext

Click Therapeutics is a New York-based private digital therapeutics company developing FDA-authorized prescription software treatments for psychiatric, neurological, and cardiometabolic conditions, partnering with major pharmaceutical companies (Otsuka, Boehringer Ingelheim) and serving patients via healthcare provider prescriptions and reimbursed app downloads.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription digital therapeutics, software-enhanced drugs, digital therapeutics platform, AI-enabled therapeutics, neuromodulatory treatments
Industry5 codes
PRIMARYHLACANAB
Prescription Digital Therapeutics (PDT)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAJ
Digital Rehabilitation & Physical Therapy Therapeutics
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code3 codes
  • Offices of Physicians6211
  • Outpatient Mental Health and Substance Abuse Centers621420
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
Prescription Digital Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing royalties & milestone payments from pharma partners
TypeLicensing Royalties
Description

Click receives upfront payments, R&D funding, regulatory and commercial milestone payments, and tiered (often double-digit) royalties on net sales from pharma co-development partners. From Otsuka: up to $10M upfront/regulatory + ~$20M development funding + $272M in commercial milestones + tiered double-digit royalties on global Rejoyn sales. From Boehringer: original deal value over $500M (CT-155) plus $460M for CT-156 expansion + tiered royalties.

clicktherapeutics.com
2Prescription digital therapeutic sales (Rejoyn, CT-132, AspyreRx)
TypeSubscription Recurring
Description

Revenue from commercialization of FDA-authorized prescription digital therapeutics via app store downloads and payer (Medicare/private insurance) reimbursement; now extending to in-house commercialization of CT-155 after April 2026 Boehringer restructuring.

clicktherapeutics.com
3Click SE™ Software-Enhanced Drug™ B2B platform deals
TypeProfessional Services
Description

B2B platform revenue from pharma collaborators developing "SE" (software-enhanced) versions of pipeline or marketed drugs, combining Click's software with their pharmacotherapy to support added clinical benefit claims under PDURS guidance.

3ds.com
Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details3 tiers
1Rejoyn (CT-152) - six-week prescription digital therapeutic for MDD; covered by Medicare reimbursement
ModelOtherBilling cadencePay-as-you-go
Notes

Prescription required; downloaded from iOS/Android app stores; reimbursed by Medicare and select payers; exact price not publicly disclosed.

clicktherapeutics.com
2Ultrahuman Ring Air Migraine PowerPlug (embedding CT-132) - consumer pricing pending
ModelOtherBilling cadencePay-as-you-go
Notes

Available through the Ultrahuman app in early 2026 across Europe, the USA and Canada; pricing details still pending per launch coverage.

basic-tutorials.com
3Click SE™ Software-Enhanced Drug™ deals - quote-based enterprise partnerships
ModelOtherBilling cadenceMulti-year contract
Notes

B2B licensing/co-development agreements with pharmaceutical companies; quote-based / not publicly disclosed.

clicktherapeutics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Click SE
Description

Click Therapeutics' product offering for Software-Enhanced Drug™ therapies, launched in October 2024 in response to FDA draft guidance on Prescription Drug Use-Related Software (PDURS); combines Click's digital therapeutic technology with pharmacotherapy to create software-enhanced drug treatments with added clinical benefit.

businesswire.com
+2 more records
Core offering1 text field

Click Therapeutics develops, validates, and commercializes software as prescription medical treatments, delivered to patients via smartphone and prescribed by physicians. Its portfolio includes FDA-cleared prescription digital therapeutics (Rejoyn for MDD, CT-132 for episodic migraine, AspyreRx for type 2 diabetes) and the Click SE Software-Enhanced Drug platform that combines the company's digital therapeutics with partner pharmacotherapies to deliver added clinical benefit.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • CT-132 reduced monthly migraine days by -3.04 MMDs vs sham (treatment difference -0.9 MMDs; p=0.005) in 568 ITT participants over 12 weeks
+4 more records
Product overview1 text field

Click Therapeutics operates a platform-plus-modules architecture, anchored by its proprietary AI-enabled digital therapeutics platform that combines neuroscience with software to develop, validate, and commercialize software as prescription medical treatments. The mature commercial portfolio includes the FDA-cleared Rejoyn (CT-152) for Major Depressive Disorder, the FDA-authorized CT-132 for episodic migraine prevention, and the FDA-authorized AspyreRx for type 2 diabetes (acquired from Better Therapeutics). The investigational pipeline spans psychiatry, neurology, oncology, immunology, and cardiometabolic diseases, including CT-155 (schizophrenia, Phase III positive), CT-156 (schizophrenia), CT-102 (opioid use disorder), CT-133 (multiple sclerosis), CT-171 (atopic dermatitis), CT-181 (obesity, leveraging AspyreRx), CT-191 (oncology), CT-141/Clickadian (insomnia), and CT-111/Clickheart (acute coronary syndrome). Building on this foundation, Click launched Click SE™ in October 2024 to combine its digital therapeutic technology with pharmacotherapy, creating Software-Enhanced Drug™ therapies under the FDA's PDURS framework. Cross-platform integrations include the Migraine PowerPlug with Ultrahuman's Ring Air smart ring for biomarker-driven migraine management.

Product and service15 records
1Click Therapeutics AI-Enabled Digital Therapeutics Platform
CategoryDigital therapeutics platform / core technology
Description

Proprietary, multimodal, platform-based foundation that combines scientifically proven therapies with proprietary Digital Neuroactivation and Modulation (DiNaMo) mechanisms and AI-based technologies to develop, validate, and commercialize software as prescription medical treatments for patients with unmet medical needs.

2Rejoyn (CT-152)
CategoryPrescription digital therapeutic
Description

First FDA-cleared prescription digital therapeutic for the adjunctive treatment of Major Depressive Disorder (MDD) symptoms in adults age 22+ on antidepressant medication. Six-week smartphone-delivered treatment combining clinically-validated Emotional Faces Memory Task (EFMT) cognitive emotional training with brief therapeutic lessons; co-developed with Otsuka Pharmaceutical.

3CT-132
CategoryPrescription digital therapeutic
Description

First FDA-authorized (De Novo, April 2025) prescription digital therapeutic for the preventive treatment of episodic migraine in adults 18+, for adjunctive use alongside acute and/or other preventive treatments. 12-week clinical intervention modulating sensory, autonomic, and affective neurocircuitry through CBT and evidence-based practices; -3.04 MMD absolute reduction in pivotal ReMMi-D trial.

4AspyreRx
CategoryPrescription digital therapeutic
Description

FDA-authorized prescription digital therapeutic providing cognitive behavioral therapy to adults 18+ with type 2 diabetes as adjunctive therapy to standard of care. Acquired from Better Therapeutics in May 2024; also received FDA Breakthrough Device Designation for metabolic dysfunction-associated steatohepatitis (MASH). Click is integrating AspyreRx with its AI-enabled platform to optimize CT-181 for combination use with GLP-1s.

5CT-155
CategoryInvestigational prescription digital therapeutic
Description

Investigational prescription digital therapeutic designed to treat the negative symptoms of schizophrenia as adjunctive therapy to standard of care antipsychotic therapy. FDA Breakthrough Device Designation granted January 2024; co-developed with Boehringer Ingelheim since September 2020. Phase III CONVOKE trial met primary endpoint in August 2025, showing 62% relative improvement in CAINS-MAP.

6CT-156
CategoryInvestigational prescription digital therapeutic
Description

Investigational prescription digital therapeutic for schizophrenia, added under the expanded Click-Boehringer Ingelheim collaboration (announced December 2022) to address additional unmet needs in schizophrenia. Currently in Phase 2 development/pilot stage, complementing the CT-155 program.

7CT-102
CategoryInvestigational prescription digital therapeutic
Description

Prescription digital therapeutic candidate for Opioid Use Disorder (OUD), developed in collaboration with Indivior as part of Click's psychiatry, CNS, and pain disorders portfolio. Currently in Phase 2 development/pilot stage.

8CT-133
CategoryInvestigational prescription digital therapeutic
Description

Prescription digital therapeutic candidate for Multiple Sclerosis (MS) in Click's neurology pipeline. Currently in Phase 1 (Discovery) stage of development.

9CT-171
CategoryInvestigational prescription digital therapeutic
Description

Prescription digital therapeutic candidate for Atopic Dermatitis in Click's immunology pipeline. Currently in Phase 1 (Discovery) stage of development.

10CT-181
CategoryInvestigational prescription digital therapeutic
Description

Prescription digital therapeutic candidate for Obesity optimized for combination use with anti-obesity and diabetes medications such as GLP-1s (including current injectables and future oral formulations) to improve treatment persistence, outcomes, and value. Currently in Phase 1 (Discovery) stage, leveraging AspyreRx's clinically validated digital behavioral therapy and Click's AI-enabled platform.

11CT-191
CategoryInvestigational prescription digital therapeutic
Description

Prescription digital therapeutic candidate for Oncology in Click's oncology pipeline. Currently in Phase 1 (Discovery) stage, including a randomized controlled pilot trial of a neuromodulatory digital therapeutic for individuals with breast cancer (Adler et al., 2025).

12CT-141 (Clickadian)
CategoryInvestigational prescription digital therapeutic
Description

Prescription digital therapeutic candidate branded as Clickadian for Insomnia. Currently in Phase 1 (Discovery) stage of development.

13CT-111 (Clickheart)
CategoryInvestigational prescription digital therapeutic
Description

Prescription digital therapeutic candidate branded as Clickheart for Acute Coronary Syndrome. Currently in Phase 1 (Discovery) stage of development as part of Click's cardiology pipeline.

14Click SE (Software-Enhanced Drug Therapies)
CategorySoftware-enhanced drug platform offering
Description

B2B product offering that combines Click's patent-protected and clinically validated digital therapeutic technology with pharmacotherapy to create Software-Enhanced Drug treatments, designed to deliver added clinical benefit to patients compared to drug alone and to support label enhancement claims under FDA PDURS guidance for pharmaceutical partners.

15Ultrahuman Migraine PowerPlug
CategoryWearable-integrated digital therapeutic feature
Description

Software-based feature integrated into Ultrahuman's Ring Air smart ring platform that combines Ultrahuman's biometric tracking (sleep, HRV, stress, activity) with Click's FDA-authorized CT-132 digital therapeutic technology to deliver biomarker-driven personalized migraine insights and guided behavioral interventions.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-01-14
Description

Partnership to develop the Migraine PowerPlug, a biomarker-driven migraine management tool that integrates Click's FDA-authorized prescription digital therapeutic CT-132 with Ultrahuman's smart ring platform. Uses sleep, HRV, stress and activity data to deliver personalized migraine insights and guided behavioral interventions. Scheduled for early 2026 launch in US, Canada, EU, India and Australia.

2Better Therapeutics
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-05-22
Description

Click acquired the assets of Better Therapeutics, Inc. in May 2024 to accelerate development in obesity and cardiometabolic disease. Assets included AspyreRx (BT-001, first FDA-authorized PDT for type 2 diabetes), BT-002 (hypertension), BT-003 (hyperlipidemia), and BT-004 (Breakthrough Designation for MASH). Click integrates AspyreRx's clinically validated CBT with its AI-enabled platform to develop CT-181 (obesity) optimized for combination with GLP-1s.

clicktherapeutics.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-05-22
Description

Multi-year collaborative development partnership with Click Therapeutics on CT-102, a prescription digital therapeutic candidate for opioid use disorder (OUD), currently in Phase 2: Dev/Pilot stage.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-08-02
Description

Selected by Click Therapeutics as the contract research organization for the ReMMiD-C fully remote decentralized clinical trial in migraine patients on CGRP inhibitor therapy. Syneos Health provides decentralized clinical trial solutions, design expertise and operational execution alongside Click's digital therapeutic delivery via mobile app.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2021-02-24
Description

Verily's Project Baseline platform used to execute the fully remote Mirai clinical trial evaluating CT-152 in adults with MDD on antidepressant monotherapy; first-of-its-kind fully remote trial design for MDD leveraging Verily's tools and technology to engage patients and clinicians.

6Boehringer Ingelheim
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-09-11
Description

Worldwide collaboration to develop and commercialize CT-155, a prescription digital therapeutic for experiential negative symptoms of schizophrenia. Initial deal value over $500M (upfront, R&D funding, milestones, tiered royalties). Expanded December 2022 to add CT-156 (up to $460M additional milestones). CT-155 received FDA Breakthrough Designation January 2024, met primary endpoint in CONVOKE Phase III trial August 2025, and was presented at ECNP October 2025.

clicktherapeutics.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-03
Description

Co-development and commercialization partnership for CT-152 (Rejoyn), the first FDA-cleared prescription digital therapeutic for adjunctive treatment of MDD symptoms. Signed January 2019; Otsuka committed full development funding, pays Click up to $10M upfront/regulatory + ~$20M development funding + $272M in commercial milestones + tiered double-digit royalties on global sales. Mirai fully-remote pivotal trial launched February 2021 with Verily. FDA cleared Rejoyn in April 2024.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Akili Interactive is a leading prescription digital therapeutics company that developed EndeavorRx (FDA-authorized for ADHD in children) and other cognitive digital therapeutics. Akili is the closest direct peer to Click in the prescription digital therapeutics space, competing for the same payer and prescriber mindshare, though Akili has since pivoted toward broader consumer cognitive health offerings.

TypeDirect peer
Description

Big Health developed Sleepio, a prescription digital therapeutic for insomnia, and is expanding into anxiety and depression. Big Health competes directly with Click in CNS-focused PDTs and shares the same regulatory pathway, payer coverage challenges, and pharma partnership opportunities.

TypeDirect peer
Description

Mahana Therapeutics is a digital therapeutics company focused on gastrointestinal conditions (e.g., irritable bowel syndrome) that has secured FDA authorizations and pursues prescription reimbursement. Mahana competes with Click in the prescription digital therapeutics business model and is at a similar pre-commercial or early-commercial stage.

TypeDirect peer
Description

Welldoc develops prescription digital health solutions for chronic disease management including diabetes (BlueStar, the first FDA-cleared digital therapeutic for type 2 diabetes), cardiovascular, and mental health. Welldoc competes directly with Click in the cardiometabolic PDT space and pursues similar payer and pharma partnership channels.

TypeBroad incumbent
Description

Omada Health is a leading virtual chronic care company offering digital programs for diabetes prevention, diabetes management, hypertension, and behavioral health. While broader than Click's prescription model, Omada overlaps in cardiometabolic digital therapeutics and competes for similar payer contracts and employer customers.

TypeBroad incumbent
Description

Headspace Health (post-Ginger merger) provides mental health digital therapeutics and telebehavioral health services, including prescription digital mental health offerings. Headspace is a broader incumbent that overlaps with Click's Rejoyn (MDD) target market, though it primarily pursues consumer and employer channels rather than prescription reimbursement.

TypeBroad incumbent
Description

Virta Health provides a digitally delivered, clinician-led program to reverse type 2 diabetes and other metabolic conditions. Virta overlaps with Click's AspyreRx and CT-181 (obesity) pipeline in the cardiometabolic digital therapeutics space and pursues similar payer and employer channels.

8Pear Therapeutics (historical)
TypeEmerging player
Description

Pear Therapeutics was the prior category leader in prescription digital therapeutics, with FDA authorizations for reSET (substance use disorder), reSET-O (opioid use disorder), and Somryst (insomnia). Pear filed for bankruptcy in April 2023 due to insufficient payer adoption and was acquired by assets purchasers. Pear is the most cautionary historical peer for Click, illustrating both the opportunity and the execution risks in commercializing PDTs.

TypeEmerging player
Description

Limbic is a UK-based digital therapeutics company developing AI-powered cognitive behavioral therapy tools, including a CE-marked digital therapeutic for depression and anxiety, with plans to seek FDA pathway. Limbic overlaps with Click's Rejoyn (MDD) and represents an emerging European competitor in prescription-grade digital mental health.

10Better Therapeutics
TypeOthers
Description

Better Therapeutics was a digital therapeutics company that developed AspyreRx (FDA-authorized PDT for type 2 diabetes) and was acquired by Click Therapeutics in May 2024. As the direct acquirer of Better's assets, Click has effectively internalized this peer and inherited its cardiometabolic pipeline (BT-002 hypertension, BT-003 hyperlipidemia, BT-004 MASH).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Click Therapeutics

Prescription Digital Therapeuticsclicktherapeutics.com

Click Therapeutics is a New York-based private digital therapeutics company developing FDA-authorized prescription software treatments for psychiatric, neurological, and cardiometabolic conditions, partnering with major pharmaceutical companies (Otsuka, Boehringer Ingelheim) and serving patients via healthcare provider prescriptions and reimbursed app downloads.

What Click Therapeutics does

Click Therapeutics, Inc. is a New York City-based, venture-backed private digital therapeutics company founded in 2012 by David Benshoof Klein. The company develops, validates, and commercializes software as prescription medical treatments (Prescription Digital Therapeutics, or PDTs) for serious psychiatric, neurological, and cardiometabolic conditions. Its proprietary AI-enabled platform combines the Click Neurobehavioral Intervention (CNI) Platform with the Digital Neuroactivation and Modulation (DiNaMo) paradigm to deliver clinically-validated, smartphone-based cognitive and behavioral interventions that modulate neural circuits involved in depression, migraine, schizophrenia, diabetes, and other conditions. The platform supports both standalone PDTs and Click SE™ Software-Enhanced Drug™ combinations with pharmacotherapy under FDA's PDURS framework.

The company has secured three FDA-authorized products: Rejoyn (CT-152) for adjunctive MDD treatment (FDA-cleared April 2024), CT-132 for episodic migraine prevention (FDA De Novo authorization April 2025), and AspyreRx for type 2 diabetes (acquired via Better Therapeutics in May 2024). Its investigational pipeline spans schizophrenia (CT-155 in Phase III with positive CONVOKE results; CT-156 in Phase 2), opioid use disorder (CT-102 with Indivior), multiple sclerosis (CT-133), atopic dermatitis (CT-171), obesity optimized for GLP-1 combination (CT-181), oncology (CT-191), insomnia (CT-141/Clickadian), and acute coronary syndrome (CT-111/Clickheart). The FDA has granted Breakthrough Device Designations for CT-132, CT-155, and BT-004.

Click generates revenue through three primary streams: (1) licensing royalties and milestone payments from pharmaceutical co-development partners, with disclosed deal values exceeding $500M (Boehringer Ingelheim for CT-155/CT-156) and up to $302M (Otsuka for Rejoyn), plus tiered double-digit royalties on net sales; (2) direct prescription digital therapeutic sales via iOS/Android app stores reimbursed by Medicare and select commercial payers; and (3) B2B Click SE™ enterprise partnerships with pharma companies for software-enhanced drug development. Distribution is multi-channel, including prescription downloads, healthcare provider channels, pharma partner commercialization (Otsuka for Rejoyn globally; Click now leads CT-155 commercialization post-April 2026 restructuring), and OEM/embedded distribution via Ultrahuman's Ring Air smart ring (Migraine PowerPlug, launching early 2026 across the US, Canada, EU, India, and Australia). The company employs ~68 staff post-April 2026 layoffs and is led by founder/CEO David Benshoof Klein alongside a multidisciplinary executive team.

Click Therapeutics firmographics

Firmographics
Name
Click Therapeutics
Legal name
Click Therapeutics, Inc.
Website
https://clicktherapeutics.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Click Therapeutics is a New York-based private digital therapeutics company developing FDA-authorized prescription software treatments for psychiatric, neurological, and cardiometabolic conditions, partnering with major pharmaceutical companies (Otsuka, Boehringer Ingelheim) and serving patients via healthcare provider prescriptions and reimbursed app downloads.
Ownership category
akta.pro rank

Click Therapeutics industry classification

Industry
Product category
Prescription Digital Therapeutics
NAICS
Offices of Physicians (6211), Outpatient Mental Health and Substance Abuse Centers (621420), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAB
Prescription Digital Therapeutics (PDT)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAJ
Digital Rehabilitation & Physical Therapy Therapeutics
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Prescription digital therapeutics
  • Software-enhanced drugs
  • Digital therapeutics platform
  • AI-enabled therapeutics
  • Neuromodulatory treatments

Where Click Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Click Therapeutics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Licensing royalties & milestone payments from pharma partners: Click receives upfront payments, R&D funding, regulatory and commercial milestone payments, and tiered (often double-digit) royalties on net sales from pharma co-development partners. From Otsuka: up to $10M upfront/regulatory + ~$20M development funding + $272M in commercial milestones + tiered double-digit royalties on global Rejoyn sales. From Boehringer: original deal value over $500M (CT-155) plus $460M for CT-156 expansion + tiered royalties.
  2. Prescription digital therapeutic sales (Rejoyn, CT-132, AspyreRx): Revenue from commercialization of FDA-authorized prescription digital therapeutics via app store downloads and payer (Medicare/private insurance) reimbursement; now extending to in-house commercialization of CT-155 after April 2026 Boehringer restructuring.
  3. Click SE™ Software-Enhanced Drug™ B2B platform deals: B2B platform revenue from pharma collaborators developing "SE" (software-enhanced) versions of pipeline or marketed drugs, combining Click's software with their pharmacotherapy to support added clinical benefit claims under PDURS guidance.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goRejoyn (CT-152) - six-week prescription digital therapeutic for MDD; covered by Medicare reimbursement
OtherPay-as-you-goUltrahuman Ring Air Migraine PowerPlug (embedding CT-132) - consumer pricing pending
OtherMulti-year contractClick SE™ Software-Enhanced Drug™ deals - quote-based enterprise partnerships

Go-to-market motion1 record

Distribution channels5 records

Click Therapeutics product offering

Product offering

Core offering

Click Therapeutics develops, validates, and commercializes software as prescription medical treatments, delivered to patients via smartphone and prescribed by physicians. Its portfolio includes FDA-cleared prescription digital therapeutics (Rejoyn for MDD, CT-132 for episodic migraine, AspyreRx for type 2 diabetes) and the Click SE Software-Enhanced Drug platform that combines the company's digital therapeutics with partner pharmacotherapies to deliver added clinical benefit.

Product overview

Click Therapeutics operates a platform-plus-modules architecture, anchored by its proprietary AI-enabled digital therapeutics platform that combines neuroscience with software to develop, validate, and commercialize software as prescription medical treatments. The mature commercial portfolio includes the FDA-cleared Rejoyn (CT-152) for Major Depressive Disorder, the FDA-authorized CT-132 for episodic migraine prevention, and the FDA-authorized AspyreRx for type 2 diabetes (acquired from Better Therapeutics). The investigational pipeline spans psychiatry, neurology, oncology, immunology, and cardiometabolic diseases, including CT-155 (schizophrenia, Phase III positive), CT-156 (schizophrenia), CT-102 (opioid use disorder), CT-133 (multiple sclerosis), CT-171 (atopic dermatitis), CT-181 (obesity, leveraging AspyreRx), CT-191 (oncology), CT-141/Clickadian (insomnia), and CT-111/Clickheart (acute coronary syndrome). Building on this foundation, Click launched Click SE™ in October 2024 to combine its digital therapeutic technology with pharmacotherapy, creating Software-Enhanced Drug™ therapies under the FDA's PDURS framework. Cross-platform integrations include the Migraine PowerPlug with Ultrahuman's Ring Air smart ring for biomarker-driven migraine management.

Differentiator

Problem solved

Functional benefit

Brands

  • Click SE: Click Therapeutics' product offering for Software-Enhanced Drug™ therapies, launched in October 2024 in response to FDA draft guidance on Prescription Drug Use-Related Software (PDURS); combines Click's digital therapeutic technology with pharmacotherapy to create software-enhanced drug treatments with added clinical benefit.
  • Rejoyn
  • AspyreRx

Products and services

  • Click Therapeutics AI-Enabled Digital Therapeutics Platform Proprietary, multimodal, platform-based foundation that combines scientifically proven therapies with proprietary Digital Neuroactivation and Modulation (DiNaMo) mechanisms and AI-based technologies to develop, validate, and commercialize software as prescription medical treatments for patients with unmet medical needs.
  • Rejoyn (CT-152) First FDA-cleared prescription digital therapeutic for the adjunctive treatment of Major Depressive Disorder (MDD) symptoms in adults age 22+ on antidepressant medication. Six-week smartphone-delivered treatment combining clinically-validated Emotional Faces Memory Task (EFMT) cognitive emotional training with brief therapeutic lessons; co-developed with Otsuka Pharmaceutical.
  • CT-132 First FDA-authorized (De Novo, April 2025) prescription digital therapeutic for the preventive treatment of episodic migraine in adults 18+, for adjunctive use alongside acute and/or other preventive treatments. 12-week clinical intervention modulating sensory, autonomic, and affective neurocircuitry through CBT and evidence-based practices; -3.04 MMD absolute reduction in pivotal ReMMi-D trial.
  • AspyreRx FDA-authorized prescription digital therapeutic providing cognitive behavioral therapy to adults 18+ with type 2 diabetes as adjunctive therapy to standard of care. Acquired from Better Therapeutics in May 2024; also received FDA Breakthrough Device Designation for metabolic dysfunction-associated steatohepatitis (MASH). Click is integrating AspyreRx with its AI-enabled platform to optimize CT-181 for combination use with GLP-1s.
  • CT-155 Investigational prescription digital therapeutic designed to treat the negative symptoms of schizophrenia as adjunctive therapy to standard of care antipsychotic therapy. FDA Breakthrough Device Designation granted January 2024; co-developed with Boehringer Ingelheim since September 2020. Phase III CONVOKE trial met primary endpoint in August 2025, showing 62% relative improvement in CAINS-MAP.
  • CT-156 Investigational prescription digital therapeutic for schizophrenia, added under the expanded Click-Boehringer Ingelheim collaboration (announced December 2022) to address additional unmet needs in schizophrenia. Currently in Phase 2 development/pilot stage, complementing the CT-155 program.
  • CT-102 Prescription digital therapeutic candidate for Opioid Use Disorder (OUD), developed in collaboration with Indivior as part of Click's psychiatry, CNS, and pain disorders portfolio. Currently in Phase 2 development/pilot stage.
  • CT-133 Prescription digital therapeutic candidate for Multiple Sclerosis (MS) in Click's neurology pipeline. Currently in Phase 1 (Discovery) stage of development.
  • CT-171 Prescription digital therapeutic candidate for Atopic Dermatitis in Click's immunology pipeline. Currently in Phase 1 (Discovery) stage of development.
  • CT-181 Prescription digital therapeutic candidate for Obesity optimized for combination use with anti-obesity and diabetes medications such as GLP-1s (including current injectables and future oral formulations) to improve treatment persistence, outcomes, and value. Currently in Phase 1 (Discovery) stage, leveraging AspyreRx's clinically validated digital behavioral therapy and Click's AI-enabled platform.
  • CT-191 Prescription digital therapeutic candidate for Oncology in Click's oncology pipeline. Currently in Phase 1 (Discovery) stage, including a randomized controlled pilot trial of a neuromodulatory digital therapeutic for individuals with breast cancer (Adler et al., 2025).
  • CT-141 (Clickadian) Prescription digital therapeutic candidate branded as Clickadian for Insomnia. Currently in Phase 1 (Discovery) stage of development.
  • CT-111 (Clickheart) Prescription digital therapeutic candidate branded as Clickheart for Acute Coronary Syndrome. Currently in Phase 1 (Discovery) stage of development as part of Click's cardiology pipeline.
  • Click SE (Software-Enhanced Drug Therapies) B2B product offering that combines Click's patent-protected and clinically validated digital therapeutic technology with pharmacotherapy to create Software-Enhanced Drug treatments, designed to deliver added clinical benefit to patients compared to drug alone and to support label enhancement claims under FDA PDURS guidance for pharmaceutical partners.
  • Ultrahuman Migraine PowerPlug Software-based feature integrated into Ultrahuman's Ring Air smart ring platform that combines Ultrahuman's biometric tracking (sleep, HRV, stress, activity) with Click's FDA-authorized CT-132 digital therapeutic technology to deliver biomarker-driven personalized migraine insights and guided behavioral interventions.

Quantifiable outcome

  • CT-132 reduced monthly migraine days by -3.04 MMDs vs sham (treatment difference -0.9 MMDs; p=0.005) in 568 ITT participants over 12 weeks
  • +4 more outcomes

Companies that use Click Therapeutics

Customer profile

Named customers1 record

Ideal customer profiles3 records

Click Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature6 records

Click Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major, supporting and flagship.

  • UltrahumanmajorTechnology or Integration · 14 January 2026Partnership to develop the Migraine PowerPlug, a biomarker-driven migraine management tool that integrates Click's FDA-authorized prescription digital therapeutic CT-132 with Ultrahuman's smart ring platform. Uses sleep, HRV, stress and activity data to deliver personalized migraine insights and guided behavioral interventions. Scheduled for early 2026 launch in US, Canada, EU, India and Australia.
  • Better TherapeuticsmajorStrategic or Co-development Partner · 22 May 2024Click acquired the assets of Better Therapeutics, Inc. in May 2024 to accelerate development in obesity and cardiometabolic disease. Assets included AspyreRx (BT-001, first FDA-authorized PDT for type 2 diabetes), BT-002 (hypertension), BT-003 (hyperlipidemia), and BT-004 (Breakthrough Designation for MASH). Click integrates AspyreRx's clinically validated CBT with its AI-enabled platform to develop CT-181 (obesity) optimized for combination with GLP-1s.
  • IndiviorsupportingStrategic or Co-development Partner · 22 May 2024Multi-year collaborative development partnership with Click Therapeutics on CT-102, a prescription digital therapeutic candidate for opioid use disorder (OUD), currently in Phase 2: Dev/Pilot stage.
  • Syneos HealthsupportingImplementation/ SI/ Consulting Partner · 2 August 2023Selected by Click Therapeutics as the contract research organization for the ReMMiD-C fully remote decentralized clinical trial in migraine patients on CGRP inhibitor therapy. Syneos Health provides decentralized clinical trial solutions, design expertise and operational execution alongside Click's digital therapeutic delivery via mobile app.
  • Verily (Alphabet)supportingTechnology or Integration · 24 February 2021Verily's Project Baseline platform used to execute the fully remote Mirai clinical trial evaluating CT-152 in adults with MDD on antidepressant monotherapy; first-of-its-kind fully remote trial design for MDD leveraging Verily's tools and technology to engage patients and clinicians.
  • Boehringer IngelheimflagshipStrategic or Co-development Partner · 11 September 2020Worldwide collaboration to develop and commercialize CT-155, a prescription digital therapeutic for experiential negative symptoms of schizophrenia. Initial deal value over $500M (upfront, R&D funding, milestones, tiered royalties). Expanded December 2022 to add CT-156 (up to $460M additional milestones). CT-155 received FDA Breakthrough Designation January 2024, met primary endpoint in CONVOKE Phase III trial August 2025, and was presented at ECNP October 2025.
  • Otsuka PharmaceuticalflagshipStrategic or Co-development Partner · 3 January 2019Co-development and commercialization partnership for CT-152 (Rejoyn), the first FDA-cleared prescription digital therapeutic for adjunctive treatment of MDD symptoms. Signed January 2019; Otsuka committed full development funding, pays Click up to $10M upfront/regulatory + ~$20M development funding + $272M in commercial milestones + tiered double-digit royalties on global sales. Mirai fully-remote pivotal trial launched February 2021 with Verily. FDA cleared Rejoyn in April 2024.

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

Click Therapeutics competitors and assessment

Company assessment

Direct peers

  • Akili Interactive: Akili Interactive is a leading prescription digital therapeutics company that developed EndeavorRx (FDA-authorized for ADHD in children) and other cognitive digital therapeutics. Akili is the closest direct peer to Click in the prescription digital therapeutics space, competing for the same payer and prescriber mindshare, though Akili has since pivoted toward broader consumer cognitive health offerings.
  • Big Health: Big Health developed Sleepio, a prescription digital therapeutic for insomnia, and is expanding into anxiety and depression. Big Health competes directly with Click in CNS-focused PDTs and shares the same regulatory pathway, payer coverage challenges, and pharma partnership opportunities.
  • Mahana Therapeutics: Mahana Therapeutics is a digital therapeutics company focused on gastrointestinal conditions (e.g., irritable bowel syndrome) that has secured FDA authorizations and pursues prescription reimbursement. Mahana competes with Click in the prescription digital therapeutics business model and is at a similar pre-commercial or early-commercial stage.
  • Welldoc: Welldoc develops prescription digital health solutions for chronic disease management including diabetes (BlueStar, the first FDA-cleared digital therapeutic for type 2 diabetes), cardiovascular, and mental health. Welldoc competes directly with Click in the cardiometabolic PDT space and pursues similar payer and pharma partnership channels.

Broad incumbents

  • Omada Health: Omada Health is a leading virtual chronic care company offering digital programs for diabetes prevention, diabetes management, hypertension, and behavioral health. While broader than Click's prescription model, Omada overlaps in cardiometabolic digital therapeutics and competes for similar payer contracts and employer customers.
  • Headspace Health: Headspace Health (post-Ginger merger) provides mental health digital therapeutics and telebehavioral health services, including prescription digital mental health offerings. Headspace is a broader incumbent that overlaps with Click's Rejoyn (MDD) target market, though it primarily pursues consumer and employer channels rather than prescription reimbursement.
  • Virta Health: Virta Health provides a digitally delivered, clinician-led program to reverse type 2 diabetes and other metabolic conditions. Virta overlaps with Click's AspyreRx and CT-181 (obesity) pipeline in the cardiometabolic digital therapeutics space and pursues similar payer and employer channels.

Emerging players

  • Pear Therapeutics (historical): Pear Therapeutics was the prior category leader in prescription digital therapeutics, with FDA authorizations for reSET (substance use disorder), reSET-O (opioid use disorder), and Somryst (insomnia). Pear filed for bankruptcy in April 2023 due to insufficient payer adoption and was acquired by assets purchasers. Pear is the most cautionary historical peer for Click, illustrating both the opportunity and the execution risks in commercializing PDTs.
  • Limbic: Limbic is a UK-based digital therapeutics company developing AI-powered cognitive behavioral therapy tools, including a CE-marked digital therapeutic for depression and anxiety, with plans to seek FDA pathway. Limbic overlaps with Click's Rejoyn (MDD) and represents an emerging European competitor in prescription-grade digital mental health.

Others

  • Better Therapeutics: Better Therapeutics was a digital therapeutics company that developed AspyreRx (FDA-authorized PDT for type 2 diabetes) and was acquired by Click Therapeutics in May 2024. As the direct acquirer of Better's assets, Click has effectively internalized this peer and inherited its cardiometabolic pipeline (BT-002 hypertension, BT-003 hyperlipidemia, BT-004 MASH).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Click Therapeutics social profiles

Digital presence

Click Therapeutics compliance and trust

Trust signal

Compliance5 records

Click Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Click Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Click Therapeutics funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Click Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Click Therapeutics

What does Click Therapeutics do?

Click Therapeutics develops, validates, and commercializes software as prescription medical treatments, delivered to patients via smartphone and prescribed by physicians. Its portfolio includes FDA-cleared prescription digital therapeutics (Rejoyn for MDD, CT-132 for episodic migraine, AspyreRx for type 2 diabetes) and the Click SE Software-Enhanced Drug platform that combines the company's digital therapeutics with partner pharmacotherapies to deliver added clinical benefit.

Is Click Therapeutics a public or private company?

Click Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Click Therapeutics founded?

Click Therapeutics was founded in 2012. It employs 101 to 250 people.

Where is Click Therapeutics based?

Click Therapeutics is headquartered in New York, United States, in the North America region.

How does Click Therapeutics make money?

Three revenue lines are on record. Licensing royalties & milestone payments from pharma partners are the primary driver. The others are prescription digital therapeutic sales (Rejoyn, CT-132, AspyreRx) and click SE™ Software-Enhanced Drug™ B2B platform deals.

Who are Click Therapeutics's main competitors?

Direct peers on record are Akili Interactive, Big Health, Mahana Therapeutics and Welldoc. Broad incumbents are Omada Health, Headspace Health and Virta Health. Emerging players are Pear Therapeutics (historical) and Limbic. Better Therapeutics is listed as an others.

Does Click Therapeutics have an API?

No public API is recorded for Click Therapeutics.

What industry is Click Therapeutics in?

Click Therapeutics's product category is Prescription Digital Therapeutics. Its primary akta.pro industry code is HLACANAB, Prescription Digital Therapeutics (PDT), with a secondary code of HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 6211 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Bhbusiness5 Behavioral Health VC Investors to WatchVC funding in behavioral health rebounded in 2026 after a 2024 low, with large rounds like Talkiatry's $210M Series D and Grow Therapy's $150M Series D. The article highlights five firms—GreyMatter, Goldman Sachs Alternatives, Kaiser, General Catalyst, and HealthQuest—backing tech-enabled providers and specialized services.FierceBiotechMeet Motivista: Click Therapeutics debuts first-of-its-kind schizophrenia digital therapeuticClick Therapeutics received FDA 510(k) clearance for its digital therapeutic Motivista, the first treatment for negative schizophrenia symptoms. Boehringer Ingelheim provided $50 million in funding and marketing rights, with Click leading U.S. commercialization. The company will target state-level coverage, especially Medicaid, to drive adoption.SNS InsiderDigital Therapeutics for Chronic Pain Management Market Size, Share & Growth, 2026-2035The global Digital Therapeutics for Chronic Pain Management Market was valued at USD 5.21 billion in 2025 and is projected to reach USD 64.01 billion by 2035, expanding at a CAGR of 28.52% during the forecast period 2026-2035, driven by increasing adoption of AI-enabled platforms, wearable devices, and non-opioid pain management solutions. North America held approximately 46% of the market share in 2025, while the Asia Pacific region is expected to record the fastest growth at a CAGR of 33.03%. Key players including AppliedVR, Hinge Health, Sword Health, and Click Therapeutics have been actively expanding their digital therapeutic offerings, though market growth faces constraints from inconsistent reimbursement frameworks and complex regulatory requirements.TipranksClick Therapeutics Sharpens Migraine Focus and Femtech Strategy in Data-Driven Growth PushClick Therapeutics highlighted migraine as a major unmet need, noting it affects 18% of women versus 6% of men. The company is developing CT-132, a prescription digital therapeutic, and plans to enter the over-the-counter digital migraine space. It also seeks partnerships with telehealth and femtech providers to embed its offerings.TipranksClick Therapeutics Highlights Femtech Opportunity in Menstrual Migraine and Data IntegrationClick Therapeutics highlighted menstrual migraine as an under-addressed femtech gap, citing that migraine affects 18% of women versus 6% of men, with up to 60% of attacks linked to hormonal fluctuations. The company positions its digital therapeutics as a bridge to integrate fragmented cycle and symptom data into clinical care, seeking partnerships with app and wearable providers.TipranksClick Therapeutics Strategy Chief to Discuss Digital Health M&A and Growth at Industry SummitClick Therapeutics' strategy chief Austin Speier will speak at the Fast Growth Summit HealthTech on June 10 in San Francisco, focusing on digital health M&A and growth strategy. He will discuss balancing rapid product development with regulatory requirements for digital therapeutics, and may reference strategic decisions from the past year.TipranksClick Therapeutics Showcases Phase III Migraine Results and Expands Digital Health StrategyClick Therapeutics announced positive Phase III trial results for CT-132, its digital therapeutic for migraine prevention, demonstrating significant reductions in migraine days. The company also outlined its strategic expansion into digital health with Over-the-Counter Digital Therapeutics (ODTx) and Software-Enhanced Drugs (PDURS) platforms.TrendHunter.comPrescription Digital TherapeuticsClick Therapeutics secured $50 million in Series D funding from Boehringer Ingelheim to advance CT-155, its prescription digital therapeutic for adults with schizophrenia, which has received FDA Breakthrough Device designation and was co-developed with the pharmaceutical company. The deal transfers commercialization and marketing responsibility for CT-155 to Click Therapeutics, positioning the company to lead market rollout efforts. This development reflects the broader trend of digital therapeutics moving from pilot stages to market-ready medical treatments with direct commercial stewardship.GlobeNewswireMental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe mental health clinical trials market is projected to grow from $3.23 billion in 2025 to $4.89 billion by 2030, driven by rising mental health disorder prevalence, digital interventions, and regulatory support. Key trends include decentralized trial models, AI-driven patient recruitment, and digital therapeutics, with Click Therapeutics launching its prescription software product Click SE in October 2024 and Wysa partnering with April Health in March 2025. North America held the largest market share in 2025 while Asia-Pacific is projected to be the fastest-growing region by 2030, though tariffs on imported digital devices pose operational challenges.GlobeNewswireMental Health Clinical Trials Research Report 2026: $4.89 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe mental health clinical trials market is projected to grow from $3.23 billion in 2025 to $4.89 billion by 2030, driven by rising mental health disorder prevalence, digital interventions, and increased pharmaceutical research funding. Key trends include decentralized trial models, digital therapeutics, and AI-based patient recruitment tools, with companies like Click Therapeutics launching prescription software products and Wysa partnering with April Health to expand AI-driven mental health services. However, tariffs on imported digital devices pose a challenge to operational costs, prompting a shift toward local sourcing and regional partnerships.